A new an­a­lyst re­port spot­lights 3 more deaths, ARIA among Alzheimer's pa­tients tak­ing Aduhelm

A promi­nent Wall Street an­a­lyst is delv­ing back in­to the agency’s ad­verse event data­base, iden­ti­fy­ing 3 ad­di­tion­al deaths among pa­tients tak­ing the con­tro­ver­sial Alzheimer’s drug Aduhelm — though he’s care­ful to add that there is no con­clu­sive link be­tween the drug and any deaths in this group so far.

Bri­an Abra­hams at RBC, who’s stirred up some con­tro­ver­sy with an ini­tial re­port of a pa­tient death back in No­vem­ber, al­so ran some num­bers on the re­ports of ARIA seen among these pa­tients in an ef­fort to tease out just how dan­ger­ous this drug may be when used in the re­al world, as op­posed to the care­ful­ly mon­i­tored clin­i­cal tri­als Bio­gen used to ini­tial­ly test its safe­ty and ef­fi­ca­cy. ARIA in­volves brain swelling and mi­crob­leeds that could threat­en pa­tients, though Bio­gen re­searchers have in­sist­ed that it’s a safe­ty sig­nal that can be mon­i­tored and treat­ed in prac­tice.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.